Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo
| Autor: | I. Figueira, Marcio Versiani, Antonio Egidio Nardi, M. Stabl |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Imipramine Monoamine Oxidase Inhibitors Nausea medicine.drug_class Moclobemide Blood Pressure Antidepressive Agents Tricyclic Placebo Double-Blind Method Heart Rate Humans Medicine Drug Interactions chemistry.chemical_classification Depressive Disorder Monoamine oxidase inhibitor Dose-Response Relationship Drug biology business.industry Middle Aged Long-Term Care Antidepressive Agents Psychiatry and Mental health Tolerability chemistry Anesthesia Benzamides biology.protein Antidepressant Female Monoamine oxidase A medicine.symptom business Tricyclic medicine.drug |
| Zdroj: | Acta Psychiatrica Scandinavica. 82:24-28 |
| ISSN: | 1600-0447 0001-690X |
| DOI: | 10.1111/j.1600-0447.1990.tb05320.x |
| Popis: | Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies. Pooled data from these studies, comprising 1656 patients, as well as the consideration of individual trials, show that moclobemide is far better tolerated than the TCAs. Its side effects mainly comprise mild degrees of nausea and dizziness at the beginning of treatment in a small proportion of patients. Age and sex do not affect the tolerability of moclobemide: it is equally well tolerated by elderly patients. In 2300 patients treated with moclobemide in doses up to 600 mg/day, without dietary restrictions, there was no tyramine-related hypertensive reaction. It is concluded that moclobemide may be the second-generation antidepressant doctors were waiting for - equally effective as the classical antidepressants but far better tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text